Next Level Private LLC Increases Position in Bristol Myers Squibb Company $BMY

Posted by Francis Steltz on Aug 10th, 2026

Next Level Private LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 12.4% during the 2nd quarter, Holdings Channel reports. The firm owned 73,247 shares of the biopharmaceutical company’s stock after acquiring an additional 8,093 shares during the period. Bristol Myers Squibb comprises 0.8% of Next Level Private LLC’s investment portfolio, making the stock its 27th biggest position. Next Level Private LLC’s holdings in Bristol Myers Squibb were worth $4,220,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Allied Private Wealth LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth $138,000. Roan Capital Partners raised its holdings in Bristol Myers Squibb by 5.0% during the second quarter. Roan Capital Partners now owns 4,589 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 218 shares during the period. Valeo Financial Advisors LLC lifted its position in shares of Bristol Myers Squibb by 2.6% in the second quarter. Valeo Financial Advisors LLC now owns 29,784 shares of the biopharmaceutical company’s stock valued at $1,716,000 after acquiring an additional 753 shares in the last quarter. MRA Advisory Group purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at about $1,363,000. Finally, Platt Investment Counsel LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $491,000. Institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Bristol Myers Squibb Trading Down 0.1%

Shares of Bristol Myers Squibb stock opened at $64.63 on Monday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The business has a 50-day moving average price of $58.71 and a 200-day moving average price of $58.66. The firm has a market cap of $132.02 billion, a price-to-earnings ratio of 14.24, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the business earned $1.46 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.96 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BMY shares. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler began coverage on Bristol Myers Squibb in a report on Wednesday. They issued an “overweight” rating on the stock. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Get Our Latest Stock Report on BMY

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.